BioLife Solutions, Inc.

NASDAQ:BLFS

Medical - Instruments & Supplies

Healthcare
$38.61 +1.56%

+$0.40 today

Market cap
$1.89B
Beta
1.97
P/E (TTM)
-119.9
EPS (TTM)
-$0.22
52W Low $17.86High $29.62

Volume 4.39M

Average 0.52M

BLFS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

BioLife Solutions, Inc.NASDAQ: BLFS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $17.41M rose 10.3% year over year, ahead of the +7.9% change in trailing-twelve-month gross profit. Sequentially, it rose 37.3% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.

Context

  • Gross profit amounted to 64.6% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.3% holds above the trailing-twelve-month pace of +7.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.41M+37.3% QoQ
Last fiscal yearDec 2025
$62.12M+15.7% YoY
LTMMar 2026
$63.74M+7.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%——
1 year+15.7%——
3-year CAGR+9.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
62.12M USD
Year-over-year change
+15.7%
4-year CAGR
+21.1%

Gross Profit vs competitors

How BLFS compares with its peers on the latest reported figures

  • BLFS's LTM Mar 2026 gross profit of $63.74M is the 9th highest of the 11 companies compared; the peer median is $248.45M.
  • Its year-over-year change of +7.9% is the 7th highest of 11, against a peer median of +12.6%.
  • Gross profit amounts to 63.9% of revenue for BLFS, versus a peer median of 68.0%.
BLFS Competitors Peer median
Gross Profit for BLFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$507.13M +5.7%+4.9%75.2%
ATRCAtriCure, Inc.LTM Jun 2026$433.85M +16.2%+17.4%76.2%
NEOGNeogen CorporationLTM Aug 2026$418.98M +14.9%+0.2%47.4%
PHRPhreesia, Inc.LTM Apr 2026$326.13M +10.3%+23.9%65.8%
AZTAAzenta, Inc.LTM Sep 2026$274.96M +0.1%+5.6%44.2%
STAASTAAR Surgical CompanyLTM Apr 2026$221.94M +7.4%-6.5%76.4%
HROWHarrow Health, Inc.LTM Mar 2026$199.11M +25.5%+47.9%74.1%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$185.29M +41.2%+11.1%70.2%
BLFSBioLife Solutions, Inc.LTM Mar 2026$63.74M +7.9%+9.8%63.9%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$40.81M +127.1%—48.8%
PLSEPulse Biosciences, Inc.LTM Jun 2026-$256K +4.1%—21.6%
Peer median (excluding BLFS) $248.45M+12.6%+8.4%68.0%

Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue119.16M76.24M75.86M82.25M96.21M
Cost of Revenue90.31M29.33M96.52M28.58M34.1M
Gross Profit28.85M46.91M46.75M53.67M62.12M
Gross Margin24.2%61.5%61.6%65.3%64.6%
Research & Development11.82M14.8M18.8M7.91M7.57M
Selling, General & Admin48.09M44.93M55.97M50.15M55.37M
Operating Expenses73.34M52.83M117.58M60.8M74.25M
Depreciation & Amortization12.87M19.96M12.3M8.66M4.69M
EBITDA(16.65M)(124.18M)(45.24M)1.53M3.61M
EBITDA Margin-14.0%-162.9%-59.6%1.9%3.7%
Operating Income(35.16M)(5.92M)(23.44M)(7.13M)(1.08M)
Operating Margin-29.5%-7.8%-30.9%-8.7%-1.1%
Interest Income00000
Interest Expense485K687K1.81M719K2.71M
Other Income / Expenses6.13M1.08M4.97M(4.3M)(11M)
Income Before Tax(29.03M)(4.85M)(18.47M)(11.43M)(12.08M)
Pre-Tax Margin-24.4%-6.4%-24.4%-13.9%-12.6%
Income Tax Expense(20.12M)(5.24M)24K(38K)49K
Net Income(8.91M)(139.81M)(66.43M)(20.18M)(12.13M)
Net Margin-7.5%-183.4%-87.6%-24.5%-12.6%
EPS (Basic)(0.23)(3.29)(1.52)(0.44)(0.25)
EPS (Diluted)(0.23)(3.29)(1.52)(0.44)(0.25)
Weighted Avg Shares38.5M42.48M43.72M46.07M47.75M
Weighted Avg Shares (Diluted)38.5M42.48M43.72M46.07M48.65M

BioLife Solutions, Inc.

NASDAQ:BLFS

Intrinsic Alpha fair value

Locked

Current Price

$38.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.